|Bid||10.05 x 3000|
|Ask||12.60 x 800|
|Day's Range||10.65 - 11.04|
|52 Week Range||8.29 - 26.05|
|Beta (3Y Monthly)||3.16|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Rachel King has been the CEO of GlycoMimetics, Inc. (NASDAQ:GLYC) since 2003. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider Read More...
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 27 cents. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.
GlycoMimetics (NASDAQ:GLYC) issued a second quarter earnings report that investors will like. Its cash position was at high enough levels to cover future operational needs. GlycoMimetics ended the second quarter (Jun. 30, 2018) with $229.4 million in cash.
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 26 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
GlycoMimetics Inc’s (NASDAQ:GLYC): GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the UnitedRead More...
GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.